Jason T. Giurleo

Medicine · Health Sciences

14h-index605citations74works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(33), HER2/EGFR in Cancer Research(18), Nanofabrication and Lithography Techniques(13), CAR-T cell therapy research(11), Liver physiology and pathology(9)

Publications74 total

Supplementary Table 1 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025Open Access
Fig S5 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025Open Access
Fig S4 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025Open Access
Fig S2 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025Open Access
Fig S3 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025Open Access
Fig S1 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025Open Access
Fig S6 from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2025Open Access
Table S2 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Table S1 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Supplementary Data from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Figure S3 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Table S4 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Figure S2 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Data from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Table S3 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Figure S1 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Data from A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
2024Open Access
Aggregation and Oligomerization Characterization of ß-Lactoglobulin Protein Using a Solid-State Nanopore Sensor
Sensors·2023· 3 citedOpen Access
Data from A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation
2023Open Access
Data from Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Gavin Thurston(37), William C. Olson(30), Frank J. Delfino(26), Dangshe Ma(24), Marcus P. Kelly(23), Sosina Makonnen(22), Carlos Hickey(22), John O. DaSilva(19), Katie Yang(19), Tara M. Young(19), Christopher Daly(19), Jessica R. Kirshner(18), Julian Andreev(16), Richard Tavaré(13), Thomas Nittoli(12), Arthur Kunz(12), Andrés E. Perez Bay(12), Devon Faulkner(12), Marc W. Retter(10), Makenzie Danton(10)